【New Preclinical Data】 The effects of Il-18 inhibitor on cholangitis and liver fibtrosis in DDC-induced primary sclerosing cholangitis (PSC) model mice

We are pleased to announce that our client AprilBio Co., Ltd. (KOR) published the results of preclinical studies of IL-18 inhibitor using our DDC-induced primary sclerosing cholangitis (PSC) mouse model in the journal Biomed Pharmacother.


Title: Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease

(Kim DH et al., Biomed Pharmacother. 2023)  Article Link ► [Read Article]


In this study, SMC administered IL-18 inhibitor to DDC model mice, measured blood ALP, ALT, and AST levels, observed inflammatory cell infiltration and proliferation of reactive bile duct cells around the bile ducts by HE staining, analyzed liver fibrosis levels around the bile ducts by sirius red staining, and measured CK19 positive areas in liver using immunostaining.


In addition, we are also capable of measuring blood total bilirubin level, liver hydroxyproline level, various mRNA expression analyses, and various immunostainings for this model.


Besides the DDC model of cholangitis, we also offer the bile duct ligation-induced cholestatic liver disease (BDL) model mice.

These models can be used to evaluate the efficacy of drug candidates against cholangitis, liver inflammation and fibrosis, and hepatoprotective effects.


If you are interested in our models or have any questions, please feel free to contact us.